Results 101 to 110 of about 30,982 (215)

Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions.

open access: yes, 2023
: The underlying immunological mechanisms of immediate-type hypersensitivity reactions (HSR) to COVID-19 vaccines are poorly understood. We investigate the mechanisms of immediatetype hypersensitivity reactions to the Pfizer BNT162b2 vaccine and the ...
Justina Wei Lynn Tan (11634879)   +41 more
core   +1 more source

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19

open access: yesActa Pharmaceutica, 2023
Abstract This retrospective observational study is aimed to determine the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) vaccines against symptomatic or severe disease in COVID-19-diagnosed patients.
Mustafa Dogan, Berna Yilmaz
openaire   +3 more sources

Engineering CAR‐Macrophages With Advanced Delivery Systems for Tissue Repair

open access: yesAdvanced Science, Volume 13, Issue 51, 14 September 2026.
This review highlights how engineered macrophages equipped with chimeric antigen receptors (CAR) guide tissue repair by recognizing disease‐related targets, clearing harmful cells, and reshaping local immune environments. It summarizes macrophage biology, CAR design, delivery platforms, and functionalization strategies, and discusses emerging ...
Yixin Zhang   +8 more
wiley   +1 more source

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

open access: yes, 2022
We present an interim analysis of a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and reactogenicity of 2-dose BNT162b2 and CoronaVac in healthy ...
Cheng, Samuel M. S.   +66 more
core   +1 more source

Optic neuritis secondary to the Pfizer-BioNTech-162b2 COVID-19 vaccine managed with plasmapheresis: A case report and review

open access: yesOman Journal of Ophthalmology, 2022
Paras P Shah   +4 more
doaj   +1 more source

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 3246-3256, September 2026.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind   +7 more
wiley   +1 more source

Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain

open access: yesScientific Reports, 2022
Scarce data have been reported about cellular immunity and longevity for different COVID-19 vaccination schedules. We carried out a prospective study enrolling 709 healthcare workers receiving two doses of mRNA-1273, BNT162b2, ChAdOx1, ChAdOx1/BNT162b2 ...
Leire Fernández-Ciriza   +7 more
doaj   +1 more source

Isoform‐Level Analysis Reveals Reproducible Early Changes in Transcript Usage During Human Vaccine Responses

open access: yesEuropean Journal of Immunology, Volume 56, Issue 9, September 2026.
mRNA vaccination triggers an early, transient wave of altered transcript isoform usage peaking at 24 h and resolving by Day 14, affecting genes involved in innate immunity. Confirmed by long‐read sequencing and reproduced across influenza, Ebola, and MVA‐based vaccine cohorts, these results highlight a previously underappreciated feature of vaccine ...
Lennart Riemann   +6 more
wiley   +1 more source

Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database

open access: yesInternational Journal of General Medicine, 2021
Rimple Jeet Kaur,1 Siddhartha Dutta,1 Jaykaran Charan,1 Pankaj Bhardwaj,2 Ankita Tandon,3 Dharamveer Yadav,4 Salequl Islam,5 Mainul Haque6 1Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; 2Department of ...
Jeet Kaur R   +7 more
doaj  

Smart Design: Integrating Artificial Intelligence and Gene Editing for Advanced mRNA Therapeutics

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
The challenges of mRNA therapy and the application of artificial intelligence and gene editing in the field of mRNA drugs. ABSTRACT Artificial intelligence (AI) and gene editing are increasingly being applied to the design and evaluation of mRNA therapeutics.
Haixing Shi   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy